Praxis stock tanks after mid-stage movement disorder trial miss
Praxis Precision Medicines has missed its goal in a Phase IIb trial after rolling out positive Phase IIa results last year.
The CNS-focused biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
